344 related articles for article (PubMed ID: 20530712)
1. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T
Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
[TBL] [Abstract][Full Text] [Related]
2. Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
Zhang CC; Pavlicek A; Zhang Q; Lira ME; Painter CL; Yan Z; Zheng X; Lee NV; Ozeck M; Qiu M; Zong Q; Lappin PB; Wong A; Rejto PA; Smeal T; Christensen JG
Clin Cancer Res; 2012 Sep; 18(18):5008-19. PubMed ID: 22806875
[TBL] [Abstract][Full Text] [Related]
3. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
Samon JB; Castillo-Martin M; Hadler M; Ambesi-Impiobato A; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Jakubczak J; Randolph S; Cordon-Cardo C; Ferrando AA
Mol Cancer Ther; 2012 Jul; 11(7):1565-75. PubMed ID: 22504949
[TBL] [Abstract][Full Text] [Related]
4. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.
Arcaroli JJ; Quackenbush KS; Purkey A; Powell RW; Pitts TM; Bagby S; Tan AC; Cross B; McPhillips K; Song EK; Tai WM; Winn RA; Bikkavilli K; Vanscoyk M; Eckhardt SG; Messersmith WA
Br J Cancer; 2013 Aug; 109(3):667-75. PubMed ID: 23868008
[TBL] [Abstract][Full Text] [Related]
5. GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.
Meng X; Matlawska-Wasowska K; Girodon F; Mazel T; Willman CL; Atlas S; Chen IM; Harvey RC; Hunger SP; Ness SA; Winter SS; Wilson BS
Leukemia; 2011 Jul; 25(7):1135-46. PubMed ID: 21494254
[TBL] [Abstract][Full Text] [Related]
6. A novel triazole, NMK-T-057, induces autophagic cell death in breast cancer cells by inhibiting γ-secretase-mediated activation of Notch signaling.
Das A; Narayanam MK; Paul S; Mukhnerjee P; Ghosh S; Dastidar DG; Chakrabarty S; Ganguli A; Basu B; Pal M; Chatterji U; Banerjee SK; Karmakar P; Kumar D; Chakrabarti G
J Biol Chem; 2019 Apr; 294(17):6733-6750. PubMed ID: 30824542
[TBL] [Abstract][Full Text] [Related]
7. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
Wang K; Zhang Q; Li D; Ching K; Zhang C; Zheng X; Ozeck M; Shi S; Li X; Wang H; Rejto P; Christensen J; Olson P
Clin Cancer Res; 2015 Mar; 21(6):1487-96. PubMed ID: 25564152
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
Zhang CC; Yan Z; Zong Q; Fang DD; Painter C; Zhang Q; Chen E; Lira ME; John-Baptiste A; Christensen JG
Stem Cells Transl Med; 2013 Mar; 2(3):233-42. PubMed ID: 23408105
[TBL] [Abstract][Full Text] [Related]
9. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
Cui D; Dai J; Keller JM; Mizokami A; Xia S; Keller ET
Clin Cancer Res; 2015 Oct; 21(20):4619-29. PubMed ID: 26202948
[TBL] [Abstract][Full Text] [Related]
10. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.
Messersmith WA; Shapiro GI; Cleary JM; Jimeno A; Dasari A; Huang B; Shaik MN; Cesari R; Zheng X; Reynolds JM; English PA; McLachlan KR; Kern KA; LoRusso PM
Clin Cancer Res; 2015 Jan; 21(1):60-7. PubMed ID: 25231399
[TBL] [Abstract][Full Text] [Related]
11. Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1-Stat3.
Wu CX; Xu A; Zhang CC; Olson P; Chen L; Lee TK; Cheung TT; Lo CM; Wang XQ
Mol Cancer Ther; 2017 Aug; 16(8):1531-1543. PubMed ID: 28522590
[TBL] [Abstract][Full Text] [Related]
12. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
13. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.
Lanz TA; Wood KM; Richter KE; Nolan CE; Becker SL; Pozdnyakov N; Martin BA; Du P; Oborski CE; Wood DE; Brown TM; Finley JE; Sokolowski SA; Hicks CD; Coffman KJ; Geoghegan KF; Brodney MA; Liston D; Tate B
J Pharmacol Exp Ther; 2010 Jul; 334(1):269-77. PubMed ID: 20363853
[TBL] [Abstract][Full Text] [Related]
15. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
[TBL] [Abstract][Full Text] [Related]
16. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein.
Yang T; Arslanova D; Gu Y; Augelli-Szafran C; Xia W
Mol Brain; 2008 Nov; 1():15. PubMed ID: 18983676
[TBL] [Abstract][Full Text] [Related]
17. HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
Du Z; Li L; Sun W; Wang X; Zhang Y; Chen Z; Yuan M; Quan Z; Liu N; Hao Y; Li T; Wang J; Luo C; Wu X
Int J Oncol; 2018 Jul; 53(1):99-112. PubMed ID: 29658567
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.
Tammam J; Ware C; Efferson C; O'Neil J; Rao S; Qu X; Gorenstein J; Angagaw M; Kim H; Kenific C; Kunii K; Leach KJ; Nikov G; Zhao J; Dai X; Hardwick J; Scott M; Winter C; Bristow L; Elbi C; Reilly JF; Look T; Draetta G; Van der Ploeg L; Kohl NE; Strack PR; Majumder PK
Br J Pharmacol; 2009 Nov; 158(5):1183-95. PubMed ID: 19775282
[TBL] [Abstract][Full Text] [Related]
19. γ-Secretase inhibitors for breast cancer and hepatocellular carcinoma: From mechanism to treatment.
Jia H; Wang Z; Zhang J; Feng F
Life Sci; 2021 Mar; 268():119007. PubMed ID: 33428878
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780.
Wang M; Wu L; Wang L; Xin X
Biochem Biophys Res Commun; 2010 Feb; 393(1):144-9. PubMed ID: 20117093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
